Last reviewed · How we verify

Remimazolam based total intravenous anesthesia

The First Affiliated Hospital of Anhui Medical University · FDA-approved active Small molecule

Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anesthesia.

Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anesthesia. Used for Induction and maintenance of general anesthesia in adults, Sedation during procedural anesthesia.

At a glance

Generic nameRemimazolam based total intravenous anesthesia
SponsorThe First Affiliated Hospital of Anhui Medical University
Drug classBenzodiazepine
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Remimazolam potentiates the inhibitory effects of GABA at GABA-A receptors in the central nervous system, leading to sedation, anxiolysis, and anesthesia. As an ester-based benzodiazepine, it is rapidly metabolized by non-specific esterases, providing a shorter duration of action compared to traditional benzodiazepines. When used as part of total intravenous anesthesia (TIVA), it serves as the sedative-hypnotic component alongside opioids and other agents.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: